Bank Pictet & Cie Europe AG Reduces Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bank Pictet & Cie Europe AG lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,467 shares of the biotechnology company’s stock after selling 360 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Sarepta Therapeutics were worth $300,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in SRPT. Wellington Management Group LLP lifted its stake in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at approximately $79,425,000. Janus Henderson Group PLC lifted its stake in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares during the period. Soros Fund Management LLC purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at approximately $25,800,000. Finally, Swedbank AB purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $16,706,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

SRPT has been the subject of a number of analyst reports. Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Robert W. Baird reduced their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $107.95 on Friday. The company has a market cap of $10.31 billion, a P/E ratio of 86.36 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s fifty day moving average price is $119.42 and its 200-day moving average price is $124.72.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.